

John J Kraiss

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4270753/publications.pdf>

Version: 2024-02-01

20
papers

1,174
citations

516710

16
h-index

752698

20
g-index

25
all docs

25
docs citations

25
times ranked

1512
citing authors

#	ARTICLE	IF	CITATIONS
1	Replication Gaps Underlie BRCA Deficiency and Therapy Response. <i>Cancer Research</i> , 2021, 81, 1388-1397.	0.9	104
2	ATF3 coordinates serine and nucleotide metabolism to drive cell cycle progression in acute myeloid leukemia. <i>Molecular Cell</i> , 2021, 81, 2752-2764.e6.	9.7	28
3	Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. <i>Molecular Cell</i> , 2021, 81, 3128-3144.e7.	9.7	142
4	RNF168-mediated localization of BARD1 recruits the BRCA1-PALB2 complex to DNA damage. <i>Nature Communications</i> , 2021, 12, 5016.	12.8	35
5	BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis. <i>Cancer Research</i> , 2020, 80, 4601-4609.	0.9	30
6	Ectopic RNF168 expression promotes break-induced replication-like DNA synthesis at stalled replication forks. <i>Nucleic Acids Research</i> , 2020, 48, 4298-4308.	14.5	13
7	RNF168-Mediated Ubiquitin Signaling Inhibits the Viability of <i>BRCA1</i> -Null Cancers. <i>Cancer Research</i> , 2020, 80, 2848-2860.	0.9	21
8	Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition. <i>Cancer Biology and Therapy</i> , 2019, 20, 1035-1045.	3.4	20
9	BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance. <i>Nature Communications</i> , 2019, 10, 5661.	12.8	45
10	Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. <i>Nature Communications</i> , 2018, 9, 3970.	12.8	192
11	BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. <i>Cell Reports</i> , 2018, 24, 3513-3527.e7.	6.4	61
12	Antitumor Synergism and Enhanced Survival with a Tumor Vasculature-Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1855-1865.	4.1	8
13	The BRCA1-11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. <i>Cancer Research</i> , 2016, 76, 2778-2790.	0.9	208
14	RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance. <i>Journal of Clinical Investigation</i> , 2016, 126, 3145-3157.	8.2	74
15	Engineering pH responsive fibronectin domains for biomedical applications. <i>Journal of Biological Engineering</i> , 2015, 9, 6.	4.7	9
16	Targeting single-walled carbon nanotubes for the treatment of breast cancer using photothermal therapy. <i>Nanotechnology</i> , 2013, 24, 375104.	2.6	55
17	Antitumor Activity of an Enzyme Prodrug Therapy Targeted to the Breast Tumor Vasculature. <i>Cancer Investigation</i> , 2013, 31, 505-510.	1.3	17
18	Purine Nucleoside Phosphorylase Targeted by Annexin V to Breast Cancer Vasculature for Enzyme Prodrug Therapy. <i>PLoS ONE</i> , 2013, 8, e76403.	2.5	16

#	ARTICLE	IF	CITATIONS
19	A programmable implementation of neural signal processing on a smartdust for brain-computer interfaces. , 2009, , .		0
20	ATF3 Coordinates Serine and Nucleotide Metabolism to Drive Cell Cycle Progression in Acute Myeloid Leukemia. SSRN Electronic Journal, 0, , .	0.4	0